NCT04207190View on ClinicalTrials.gov

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

May 26, 2024

Study Completion Date

June 29, 2024

Conditions
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

Gemtuzumab Ozogamicin

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Talazoparib

Given PO

DRUG

Talazoparib Tosylate

Given PO

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

21201

University of Maryland Greenebaum Cancer Center, Baltimore

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT04207190 - Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter